Price T Rowe Associates Inc. MD Has $581,000 Stock Position in CareDx, Inc (NASDAQ:CDNA)

Price T Rowe Associates Inc. MD boosted its position in CareDx, Inc (NASDAQ:CDNA) by 12.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 27,116 shares of the company’s stock after purchasing an additional 3,016 shares during the period. Price T Rowe Associates Inc. MD owned about 0.05% of CareDx worth $581,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Sterling Capital Management LLC lifted its stake in CareDx by 771.2% in the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company’s stock valued at $27,000 after purchasing an additional 1,126 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company’s stock valued at $84,000 after purchasing an additional 3,322 shares during the last quarter. Plato Investment Management Ltd grew its position in shares of CareDx by 34.1% in the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock valued at $116,000 after purchasing an additional 1,370 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in shares of CareDx by 41.5% in the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company’s stock valued at $200,000 after purchasing an additional 2,742 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of CareDx in the fourth quarter valued at approximately $208,000.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Stephens reaffirmed an “overweight” rating and issued a $40.00 target price on shares of CareDx in a research report on Monday, May 5th. StockNews.com downgraded CareDx from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and decreased their target price for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. HC Wainwright reiterated a “neutral” rating and issued a $25.00 price target on shares of CareDx in a research report on Monday, May 5th. Finally, The Goldman Sachs Group dropped their price target on shares of CareDx from $34.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $30.33.

Insider Activity at CareDx

In other CareDx news, Director Peter Maag sold 13,281 shares of the business’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total transaction of $228,831.63. Following the sale, the director now owns 316,743 shares of the company’s stock, valued at approximately $5,457,481.89. The trade was a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christine Cournoyer sold 16,700 shares of the business’s stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total transaction of $235,971.00. Following the sale, the director now directly owns 37,045 shares in the company, valued at approximately $523,445.85. The trade was a 31.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,246 shares of company stock valued at $469,498 over the last three months. 4.90% of the stock is owned by insiders.

CareDx Trading Up 6.5%

NASDAQ CDNA opened at $16.36 on Tuesday. CareDx, Inc has a 1-year low of $12.90 and a 1-year high of $34.84. The company has a 50 day moving average of $17.79 and a 200-day moving average of $21.09. The company has a market cap of $910.94 million, a price-to-earnings ratio of -6.06 and a beta of 2.27.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. The business had revenue of $84.69 million for the quarter, compared to analysts’ expectations of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.03) earnings per share. On average, equities research analysts forecast that CareDx, Inc will post -0.9 earnings per share for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.